← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #635 OF 1,000 MOST-CITED

Rejecting When Specifications Not Met

FDA cited this observation 35 times across 33 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs35
BY FISCAL YEAR
FY20262
FY20253
FY20242
FY20235
FY20213
FY20202
FY20194
FY20185
FY20176
FY20163

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 6.7× the rate of the average FDA-cited firm (51.5% vs 7.7%), across 33 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Failure to reject any lot of drug product containers that did not meet the appropriate written specifications for identity, strength, quality, and purity.

Eosera, Inc. · Fort Worth, Texas · Drugs · 2026-03-20

Failure to reject any lot of components that did not meet the appropriate written specifications for identity, strength, quality, and purity.

American Regent, Inc. · New Albany, Ohio · Drugs · 2026-01-29

Failure to reject any lot of components that did not meet the appropriate written specifications for identity, strength, quality, and purity.

Sri Krishna Pharmaceuticals Limited · Hyderabad · Drugs · 2025-06-27

Failure to reject any lot of components that did not meet the appropriate written specifications for identity, strength, quality, and purity.

Sani-Care Salon Products, Inc · Cartersville, Georgia · Drugs · 2025-01-17

Failure to reject any lot of components that did not meet the appropriate written specifications for identity, strength, quality, and purity.

Cosco International, Inc. · Marietta, Georgia · Drugs · 2024-10-25

Failure to reject any lot of components that did not meet the appropriate written specifications for identity, strength, quality, and purity.

Opti Source International · Bellport, New York · Drugs · 2024-04-04

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →